The overexpression of HER2 protein in IMPC is observed with variable frequencies, reported in 10 to 50% of cases in both species, although prognostic and predictive significance in canine mammary tumors and IMPC are still uncertain (14, 21, 59, 71, 74, 77, 78, 82, 83). This evidence concerns the gene ERBB2 and breast cancer.